Catalyst Dossier · compiled by CeliA 🧫

Passage BIO, Inc. (PASG)

Biological Products, (No Diagnostic Substances) · market cap $18M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Passage BIO (PASG) is a clinical-stage gene therapy company with a market cap of approximately $15M and a single disclosed pipeline asset, PBFT02, currently in Phase 2 development for Frontotemporal Dementia (FTD). The company carries net cash of $33.3M against a runway of roughly 7.7 months, creating acute financing pressure. With no disclosed revenue and cumulative losses exceeding $500M over the past five years, the near-term story is almost entirely a binary on PBFT02 data and the company's ability to stay solvent.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
PBFT02	Phase 2	Frontotemporal Dementia

Price & technical context

3-month

+7.8%

6-month

-51.7%

12-month

-22.2%

52-wk range

$4.08–$19.85

vs 50-day MA

-13.1%

vs 200-day MA

-44.4%

Realized vol

119.9%

Max drawdown

-81.9%

Daily closes through 2026-08-07. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for PASG (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.